Citation: Michael Kreuter,David J. Lederer,Maria Molina-Molina,Imre Noth,Claudia Valenzuela,Lutz Frankenstein,Derek Weycker,Mark Atwood,Klaus-Uwe Kirchgaessler,Vincent Cottin, (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. CHEST, Volume 156, Issue 4, October 2019, Pages 706-714. https://www.sciencedirect.com/science/article/pii/S0012369219308827 Background Angiotensin peptides have been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis. Angiotensin modulators are used to treat arterial hypertension, a frequent comorbidity of IPF. […]
Tag: Pulmonary Fibrosis
Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction
Citation: Zheng, Z., Peng, F., Zhou, Y. (2024). Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction. Chinese Medical Journal Pulmonary and Critical Care Medicine. https://doi.org/10.1016/j.eclinm.2021.101009 Abstract Background: Idiopathic pulmonary fibrosis (IPF) and pleuroparenchymal fibroelastosis (PPFE) are known tohave poor outcomes but detailed examinations […]
September is Pulmonary Fibrosis Awareness Month
September is Pulmonary Fibrosis (PF) Awareness Month. During this month, health charities, research institutes and support groups around the world provide information about Pulmonary Fibrosis. Pulmonary fibrosis is a progressive, incurable disease that affects the tissues in the lungs resulting in lung scarring. Overtime, this leads to a decline in lung function. Sufferers will notice […]
The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis
AbstractThe idiopathic form of pleuroparenchymal fibroelastosis (PPFE) is categorized as a rare idiopathic interstitial pneumonia in the current classification. The majority of PPFE cases are idiopathic, but many predisposing factors or comorbidities have been reported. Although histological PPFE is predominantly located in the upper lobes, which are less often affected by fibrosis in patients with […]
Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
Citation: Kumar V, Hertz M, Agro A and Byrne AJ (2023) Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis. Front. Immunol. 14:1260503. doi: 10.3389/fimmu.2023.1260503 Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite […]
September is Pulmonary Fibrosis (PF) Awareness Month
September is Pulmonary Fibrosis (PF) Awareness Month. During this month, health charities, research institutes and support groups around the world provide information about Pulmonary Fibrosis. Pulmonary fibrosis is a progressive, incurable disease that affects the tissues in the lungs resulting in lung scarring. Overtime, this leads to a decline in lung function. Sufferers will notice […]
Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
Abstract Exercise is a well-documented safe and effective intervention for prevention and rehabilitation of chronic diseases. Idiopathic pulmonary fibrosis (IPF) is a chronic deadly lung disease associated with severe signs and symptoms, exercise intolerance, diminished quality of life and poor prognosis. In the short term, supervised exercise training programmes have demonstrated clinical benefits in improving […]
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, […]
Plasticity towards Rigidity: A Macrophage Conundrum in
Pulmonary Fibrosis
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, and ultimately fatal diffuse parenchymal lung disease. The molecular mechanisms of fibrosis in IPF patients are not fully understood and there is a lack of effective treatments. For decades, different types of drugs such as immunosuppressants and antioxidants have been tested, usually with unsuccessful results. Although […]
TIPAL
TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is […]